Risk factors
Scynexis (SCYX) risk factors
Item 1A of every Scynexis Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks6 new7 dropped13 reworded
SCY-247 now dominates development, safety, approval, manufacturing and competition risks, replacing much of the prior ibrexafungerp focus.
Filed Mar 04, 2026 - FY2024 10-K risk factors56 risks
The company relies heavily on the GSK License Agreement for ibrexafungerp commercialization and revenue.
Filed Mar 12, 2025